674 related articles for article (PubMed ID: 16356796)
1. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
7. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.
Rinnab L; Blumstein NM; Mottaghy FM; Hautmann RE; Küfer R; Hohl K; Reske SN
BJU Int; 2007 Jun; 99(6):1421-6. PubMed ID: 17355373
[TBL] [Abstract][Full Text] [Related]
8. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
9. Choline-PET in prostate cancer management: the point of view of the radiation oncologist.
De Bari B; Alongi F; Lestrade L; Giammarile F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):234-47. PubMed ID: 24813466
[TBL] [Abstract][Full Text] [Related]
10. PET in the management of urologic malignancies.
Kumar R; Zhuang H; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1141-53, ix. PubMed ID: 15488563
[TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
13. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
Langsteger W; Heinisch M; Fogelman I
Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
15. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.
Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S
Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750
[TBL] [Abstract][Full Text] [Related]
16. [Visualization of prostate cancer with 11C-choline positron emission tomography (PET): localization of primary and recurrent prostate cancer].
Kanda T; Nakagomi K; Goto S; Torizuka T
Hinyokika Kiyo; 2008 May; 54(5):325-32. PubMed ID: 18546855
[TBL] [Abstract][Full Text] [Related]
17. PET in prostate and bladder tumors.
Lee ST; Lawrentschuk N; Scott AM
Semin Nucl Med; 2012 Jul; 42(4):231-46. PubMed ID: 22681672
[TBL] [Abstract][Full Text] [Related]
18. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
19. PET/CT and radiotherapy in prostate cancer.
De Jong IJ; De Haan TD; Wiegman EM; Van Den Bergh AC; Pruim J; Breeuwsma AJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):543-52. PubMed ID: 20927021
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer: role of SPECT and PET in imaging bone metastases.
Beheshti M; Langsteger W; Fogelman I
Semin Nucl Med; 2009 Nov; 39(6):396-407. PubMed ID: 19801219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
